Discover and read the best of Twitter Threads about #her2
Most recents (12)
@TumorBoardTues @drteplinsky @MPishvaian @PTarantinoMD @DFCI_BreastOnc @KariWisinski_MD @JaniceTNBCmets @her2bc 2/4 #TumorBoardTuesday
Thurs Case🎀
Take🏠messages:
#HER2+ #BreastCancer
✅Localized, early ➡️neoadj tx w chemo + anti-HER2
✅⬆️DFS w T-DM1 for residual disease
✅Future role for T-DXd?
📚We captured @drteplinsky’s discussion in this moment: twitter.com/i/events/15831…
Thurs Case🎀
Take🏠messages:
#HER2+ #BreastCancer
✅Localized, early ➡️neoadj tx w chemo + anti-HER2
✅⬆️DFS w T-DM1 for residual disease
✅Future role for T-DXd?
📚We captured @drteplinsky’s discussion in this moment: twitter.com/i/events/15831…
@TumorBoardTues @drteplinsky @MPishvaian @PTarantinoMD @DFCI_BreastOnc @KariWisinski_MD @JaniceTNBCmets @her2bc 3/4 #TumorBoardTuesday
Thursday Case🎀
📷 TBT in an image: Take a 👀at a (simplified) guide to treatment of early stage HER2+, localized #BreastCancer!
We review KATHERINE and use of ADCs to improve OS with residual disease. Is there an evolving role for T-DXd?
Thursday Case🎀
📷 TBT in an image: Take a 👀at a (simplified) guide to treatment of early stage HER2+, localized #BreastCancer!
We review KATHERINE and use of ADCs to improve OS with residual disease. Is there an evolving role for T-DXd?
@TumorBoardTues @drteplinsky @MPishvaian @PTarantinoMD @DFCI_BreastOnc @KariWisinski_MD @JaniceTNBCmets @her2bc @dradityabardia @EricaMarieRomn1 @jacobadashek @esinghimd @BreastCaupdates 4/4 #TumorBoardTuesday
Thurs Case🎀
🙏 Anti-HER2+ tx in neoadj setting improves pCR. T-DM1 improves OS when residual disease is present.
🤔 Role for other ADCs or even neoadj setting?
➡️Be sure to join us 11.01.22 when @LeciaSequist presents a case of ALK+ #NSCLC #LungCancer
Thurs Case🎀
🙏 Anti-HER2+ tx in neoadj setting improves pCR. T-DM1 improves OS when residual disease is present.
🤔 Role for other ADCs or even neoadj setting?
➡️Be sure to join us 11.01.22 when @LeciaSequist presents a case of ALK+ #NSCLC #LungCancer
@TumorBoardTues @n8pennell @MPishvaian @ShrutiPatelMD @NarjustFlorezMD @OncBrothers @jillfeldman4 @Joshua_Reuss @JineshGheeya @ClevelandClinic 2/4 #TumorBoardTuesday
Thurs Case🎀
Take🏠
#EGFRm #NSCLC:
✅Wait on NGS- IO +TKI=⬆️tox
✅Osimertinib= ex19, 21m
✅New ADCs, small molecules= future options
✅ Re-bx on prog EGFRm- rule out small cell transformation
📚We captured @n8pennell’s discussion:
twitter.com/i/events/15780…
Thurs Case🎀
Take🏠
#EGFRm #NSCLC:
✅Wait on NGS- IO +TKI=⬆️tox
✅Osimertinib= ex19, 21m
✅New ADCs, small molecules= future options
✅ Re-bx on prog EGFRm- rule out small cell transformation
📚We captured @n8pennell’s discussion:
twitter.com/i/events/15780…
@TumorBoardTues @n8pennell @MPishvaian @ShrutiPatelMD @NarjustFlorezMD @OncBrothers @jillfeldman4 @Joshua_Reuss @JineshGheeya @ClevelandClinic 3/4 #TumorBoardTuesday
Thursday Case🎀
📷 #TBT in an image: we’ve summarized some key pts re: EGFRm #NSCLC & emerging data- hope to see more ADCs as 3L options for pts with EGFRm disease in the future!
Thursday Case🎀
📷 #TBT in an image: we’ve summarized some key pts re: EGFRm #NSCLC & emerging data- hope to see more ADCs as 3L options for pts with EGFRm disease in the future!
@TumorBoardTues @n8pennell @MPishvaian @ShrutiPatelMD @NarjustFlorezMD @OncBrothers @jillfeldman4 @Joshua_Reuss @JineshGheeya @ClevelandClinic @esinghimd @nihardesai7 @NicoGagelmann @drteplinsky @jacobadashek 4/4 #TumorBoardTuesday
Thurs Case🎀
🐟Thanks to @n8pennell for an excellent discussion about the future of #EGFRm directed therapy!
➡️Please be sure to join us in 2 weeks on 10/18/22 when @drteplinsky presents a case of
Early-stage #HER2+ #BreastCancer 😀
Thurs Case🎀
🐟Thanks to @n8pennell for an excellent discussion about the future of #EGFRm directed therapy!
➡️Please be sure to join us in 2 weeks on 10/18/22 when @drteplinsky presents a case of
Early-stage #HER2+ #BreastCancer 😀
Dr. Koichi Goto starts the lung mini oral session with results from DESTINY-Lung02 of the recently approved trastuzumab deruxtecan in #HER2 NSCLC #ESMO22
1/12 #TumorBoardTuesday
2L treatment in #HER2+ breast cancer #MBC is 🤯! @PTarantinoMD led us through latest evidence👩⚖️
➡️Here's the Thurs Case🎀
👉Grab🆓 #CME credit by answering quick❓
ALL CME 🔗: integrityce.com/tbt
CME rationale🔗: bit.ly/3NnreMW
Here we go!
2L treatment in #HER2+ breast cancer #MBC is 🤯! @PTarantinoMD led us through latest evidence👩⚖️
➡️Here's the Thurs Case🎀
👉Grab🆓 #CME credit by answering quick❓
ALL CME 🔗: integrityce.com/tbt
CME rationale🔗: bit.ly/3NnreMW
Here we go!
2/12 #TumorBoardTuesday
Thurs Case🎀
Take🏠messages:
⬆️ options to tx HER2+ #MBC
✅T-DXd >T-DM1 in 2L setting (DESTINY BREAST-03)
✅Beware ADC tox- think 🫁pneumonitis & GI w T-Dxd
✅ADC design is 🗝:
➡️Need to consider DAR, linker, ability to cause ADCC
✅ADC + IO= open ❓
Thurs Case🎀
Take🏠messages:
⬆️ options to tx HER2+ #MBC
✅T-DXd >T-DM1 in 2L setting (DESTINY BREAST-03)
✅Beware ADC tox- think 🫁pneumonitis & GI w T-Dxd
✅ADC design is 🗝:
➡️Need to consider DAR, linker, ability to cause ADCC
✅ADC + IO= open ❓
3/12 #TumorBoardTuesday
Thurs Case🎀
Take🏠messages (cont’d):
✅T-DXd active against brain mets (TUXEDO-1)
✅Triplet (tucatinib, cape, tras) also active in brain mets
✅Next up: T-DXd in HER2 LOW- trials ongoing
📚We captured the discussion here:
twitter.com/i/events/15226…
Thurs Case🎀
Take🏠messages (cont’d):
✅T-DXd active against brain mets (TUXEDO-1)
✅Triplet (tucatinib, cape, tras) also active in brain mets
✅Next up: T-DXd in HER2 LOW- trials ongoing
📚We captured the discussion here:
twitter.com/i/events/15226…
💊💊 New Tweetorial Alert 💊💊
Please take a break from your #doomscrolling and read this thread. If you have an even longer break read the paper @NEJM: nejm.org/doi/full/10.10… 1/7
Please take a break from your #doomscrolling and read this thread. If you have an even longer break read the paper @NEJM: nejm.org/doi/full/10.10… 1/7
This paper is about #PartD & cancer. It is also about #pharmacoequity (shoutout @UREssien). Not the way we typically think about equity, though. This is about how screwed you are if you need cancer treatment and your treatment happens to be covered by #PartD and not #PartB. 2/7
Half of cancer drugs are covered by #PartD. Whether you get a pill versus infusion is based on your cancer type or subtype. For #breastcancer the preferred regimens for #HER2+ cancer are infused (#PartB); for HER2-, ER/PR+ cancer preferred regimens include a #PartD drug. 3/7
#WCLC20 Dr. Nakagawa presents results from the DESTINY-Lung01 trial of trastuzumab deruxtecan (T-DXd, Enhertu). T-DXd is a HER2 antibody-drug conjugate (ADC). #LCSM @IASLC @OncoAlert
#ESMO20 Update on poziotinib in #HER2 mutant #NSCLC by Mark Socinski from the ongoing phase II ZENITH20 study. #LCSM @OncoAlert @AdventHealth
#ESMO20 There are 7 cohorts to ZENITH20, 3 have completed accrual. This presentation focuses on cohort 2, #HER2 mutant NSCLC. Heavily pretreated population with most having received IO therapy and some with prior HER2 therapy as well. #LCSM @OncoAlert
#ESMO20 Poziotinib in #HER2 mutant NSCLC had a response rate of 27.8%. Duration of response 5.1 months, median time on treatment 3.7 months, median PFS 5.5 months. #LCSM @OncoAlert
#ESMO20 Happy to share the first results of RAIN-701, a phase II study of #tarloxotinib in patients with NSCLC harboring an #EGFR exon 20 insertion or an activating #HER2 mutation and any solid tumor with an #NRG1 or ERBB gene fusion. #LCSM @OncoAlert
#ESMO20 Tarlox is given as an inactive prodrug that embeds in the cell membrane. Only when it encounters hypoxia does it undergo single electron reduction to fragment to a cell permeable, pan-HER, irreversible TKI with subnanomolar potency at EGFR, HER2 and HER4. @OncoAlert #LCSM
#ESMO20 Nice discussion of the #EGFR / #HER2 #NSCLC abstracts from @ZerAlona covering poziotinib, tarloxotinib, mobocertinib, and patritumab deruxtecan. #LCSM #OncoAlert
#ESMO20 @ZerAlona discusses the efficacy of these EGFR/HER2 TKIs, balanced by their toxicity relative to other agents #LCSM #OncoAlert
Bird’s-eye view 👁 on what to look out for @WCGIC #WorldGI2020.
Opening remarks on important data 📺 @myESMO - by Dr. Eric Van Cutsem @UZLeuven.
🟩Good to see more #PrecisionMedicine🧬
🟥#Immunotherapy #Immuno-#oncology
🟦TNT & other chemo strategies
@Annals_Oncology #OncoAlert
Opening remarks on important data 📺 @myESMO - by Dr. Eric Van Cutsem @UZLeuven.
🟩Good to see more #PrecisionMedicine🧬
🟥#Immunotherapy #Immuno-#oncology
🟦TNT & other chemo strategies
@Annals_Oncology #OncoAlert
🆕#ctDNA #liquidbiopsies 🩸🧬
👀 👇🏾at the number of #clinicaltrials cropping up in this space‼️
🇦🇺DYNAMIC-II
🇦🇺DYNAMIC-III
🇺🇸COBRA @NRGonc
🇺🇸BESPOKE
🇺🇸@SU2C
🇯🇵 CIRCULATE
🌎COLUMBIA
🇮🇹🇪🇸PEGASYS
🇬🇧TRACC
🇩🇪CIRCULATE
🇫🇷crEATE
🇩🇰IMPROVE-IT
We have 2🇺🇸studies open. #CRCSM #WorldGI2020
👀 👇🏾at the number of #clinicaltrials cropping up in this space‼️
🇦🇺DYNAMIC-II
🇦🇺DYNAMIC-III
🇺🇸COBRA @NRGonc
🇺🇸BESPOKE
🇺🇸@SU2C
🇯🇵 CIRCULATE
🌎COLUMBIA
🇮🇹🇪🇸PEGASYS
🇬🇧TRACC
🇩🇪CIRCULATE
🇫🇷crEATE
🇩🇰IMPROVE-IT
We have 2🇺🇸studies open. #CRCSM #WorldGI2020
#WORLDGI2020 This is 🆒 ☢️ 32-P EUS-guided implantation in #pancreascancer #PANCSM @myESMO @WCGIC @Annals_Oncology.
Still miles to go. OS median of 16 months pointing again to the systemic nature of disease. Need to piggyback these local approaches to better systemic. #OncoAlert
Still miles to go. OS median of 16 months pointing again to the systemic nature of disease. Need to piggyback these local approaches to better systemic. #OncoAlert
#ASCO20 Important data for #HER2 #NSCLC from the DESTINY-Lung01 study of trastuzumab deruxtecan (T-DXd, DS-8201) in previously treated, HER2 mutant NSCLC. T-DXd is an antibody drug conjugate (ADC) with a topo-I inhibitor payload linked to a trastuzumab-like IgG1 mAb. #OncoAlert
#ASCO20 Included 42 pts with #HER2 mut #NSCLC (45% with CNS metastases) treated with T-DXd 6.4mg/kg q3w. Impressive outcomes: ORR 62%, DCR 90%, mPFS 14 months! And 45% of patients still on treatment. #OncoAlert #LCSM
#ASCO20 T-DXd led to nausea in most patients (largely G1-2). Alopecia in about half; anemia and neutropenia (some G3+) also observed. Treatment emergent AEs leading to discontinuation in 24% of patients. Grade 2 interstitial lung disease seen in 12% (median onset 86d). #OncoAlert
